Thessaloniki

• A pharmacokinetics and safety study of cefiderocol in hospitalized pediatric patients from birth to less than 3 months of age with suspected … Not authorised
  2023-503757-35-00 4 Aerobic Gram-negative bacterial infections
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Not authorised
  2023-506642-23-00 4 Active Pulmonary Sarcoidosis
• Phase 3 Study of Telitacicept in Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) Not authorised
  2024-512716-21-00 5 Moderately to Severely Active Systemic Lupus Erythematosus
• A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Not authorised
  2024-519745-30-00 9 Immune Thrombocytopenia (ITP)
• A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus Not authorised
  2024-520385-57-00 3 Systemic Lupus Erythematosus
• An Open-label Phase 2b Study with Blinded Evaluation of the Combination of Amodiaquine and Potassium Canrenoate with Exenatide or Glibenclam … Not authorised
  2025-522796-28-00 4 Acute Ischemic Stroke
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Con … Pending
  2023-507757-15-01 4 Sepsis
• ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending
  2024-513824-41-00 6 Childhood non-mature-B Acute Lymphoblastic Leukemia
• Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros … Pending
  2024-518013-25-00 4 Idiopathic Pulmonary Fibrosis
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 4 Non-cystic Fibrosis Bronchiectasis
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl … Pending
  2024-519638-22-00 5 IgA nephropathy
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzapari … Pending
  2024-520043-17-00 5 Thromboprophylaxis in patients with advanced pancreatic cancer
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending
  2024-520218-23-00 10 Pulmonary Arterial Hypertension
• REGN7508 versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis after Total Knee Arthroplasty in Adult Participants Pending
  2025-520479-25-00 5 Symptomatic Venous Thromboembolism (VTE)
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• Administration of Gilteritinib to eliminate MRD in patients with AML and FLT3-ITD mutation. Pending
  2025-521875-30-00 4 Acute myeloid leukaemia
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS. Pending
  2025-521910-24-00 6 Multiple Sclerosis

Showing 1–24 of 652 trials